SEHK:1093Pharmaceuticals
CSPC Pharmaceutical Group (SEHK:1093) Could Be 115% Below Fair Value Following Drug Approval
CSPC Pharmaceutical Group (SEHK:1093) has secured marketing approval in China for its once-monthly Paliperidone Palmitate Injection for schizophrenia, a development that broadens its psychiatric and neurological drug portfolio.
See our latest analysis for CSPC Pharmaceutical Group.
The marketing approval for CSPC Pharmaceutical Group’s Paliperidone Palmitate Injection comes as momentum in the stock has recently strengthened. The 30 day share price return is 28.57%, following earlier 90 day...